Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- George Peoples, MD
LumaBridge
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States
- John Wayne Cancer Institute/providence Saint John'S Health Center
Santa Monica, California, United States
- Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
- Northside Hospital
Atlanta, Georgia, United States
- University of Cincinnati Cancer Institute
Cincinnati, Ohio, United States
- Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
- Providence Regional Medical Center
Everett, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Feb 2016
- Primary completion
- 30 Oct 2019
- Completion
- 13 Nov 2019
- Last update posted
- 12 Mar 2024
- Registered enrollment
- 26
- Registry id
- NCT02678741
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.